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The NLRP3 inﬂammasome is a protein complex involved in IL-1β and IL-18 processing that
senses pathogen- and danger-associated molecular patterns (PAMPs and DAMPs). One
step- or two step-models have been proposed to explain the tight regulation of IL-1β pro-
duction during inﬂammation. Moreover, cellular stimulation triggers adenosine triphosphate
(ATP) release and subsequent activation of purinergic receptors at the cell surface. Impor-
tantly some studies have reported roles for extracellular ATP, in NLRP3 inﬂammasome
activation in response to PAMPs and DAMPs. In this mini review, we will discuss the
link between active ATP release, purinergic signaling and NLRP3 inﬂammasome activa-
tion. We will focus on the role of autocrine or paracrine ATP export in particle-induced
NLRP3 inﬂammasome activation and discuss how particle activators are competent to
induce maturation and secretion of IL-1β through a process that involves, as a ﬁrst event,
extracellular release of endogenous ATP through hemichannel opening, and as a second
event, signaling through purinergic receptors that trigger NLRP3 inﬂammasome activation.
Finally, we will review the evidence for ATP as a key pro-inﬂammatory mediator released by
dying cells. In particular we will discuss how cancer cells dying via autophagy trigger ATP-
dependent NLRP3 inﬂammasome activation in the macrophages engulﬁng them, eliciting
an immunogenic response against tumors.
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THE NLRP3 INFLAMMASOME
Innate immunity is triggered by endogenous or environmental
danger events through assembly of the NLRP3 inﬂammasome.
The NLRP3 inﬂammasome is a cytosolic multiprotein platform
which is activated in response to a variety of signals including
infection, tissue damage, and metabolic dysregulation. Activation
of the NLRP3 inﬂammasome results in the assembly of scaffold
components: the cytoplasmic receptorNLRP3, the adaptor protein
ASC and the effector protein caspase-1 (Agostini et al., 2004; Mar-
tinon et al., 2004, 2009; Martinon and Tschopp, 2004; Kanneganti
et al., 2006; Mariathasan et al., 2006). This association leads to
the activation of caspase-1, allowing the processing of pro-IL-
1β and pro-IL-18 to their mature and secreted forms which are
biologically active. IL-1β production is a tightly controlled pro-
cess playing a pivotal role in inﬂammation and in recruitment of
neutrophils into tissues. A two-signal model has been proposed
to explain the regulation of IL-1β production. First the synthesis
of pro-IL-1β and NLRP3 is triggered by transcriptional induc-
tion via ligands for Toll-like receptors (TLRs), whereas a second
stimulus leads to inﬂammasome oligomerization, caspase-1 auto-
activation, caspase-1-dependent cleavage of pro-IL-1β and then
release of the biologically active, mature IL-1β. This second signal
may be induced by a broad variety of chemically and biologi-
cally unrelated molecules classiﬁed as either pathogen-associated
molecular patterns (PAMPs) or danger-associated molecular pat-
terns (DAMPs). DAMPs originate from environmental pollutants
including silica and asbestos (Dostert et al., 2008; Halle et al.,
2008), from vaccines such as aluminum salt (alum) adjuvant
(Eisenbarth et al., 2008) or from endogenous metabolic stresses
such as high concentration of glucose (Schroder et al., 2010),
cholesterol (Duewell et al., 2010), amyloid-β protein (Halle et al.,
2008), biglycan (Babelova et al., 2009), adenosine triphosphate
(ATP; Mariathasan et al., 2006), or monosodium urate (MSU)
crystals (Aganna et al., 2002; Eisenbarth et al., 2008). Two major
upstream mechanisms are currently proposed for NLRP3 inﬂam-
masome activation: plasma membrane disruption (for bacterial
toxins and ATP) or internalization of particulate activators by
phagocytosis (Cassel et al., 2009). Extracellular ATP (eATP) or
bacterial toxins lead to K+ efﬂux and pore formation (Pelegrin
and Surprenant, 2007). Phagocytosis of particles including silica,
alum, ﬁbrillar amyloid-β protein, or MSU was shown to result
in lysosomal destabilization/permeabilization with release of the
endosomal–lysosomal protease cathepsin B into the cytoplasm
(Halle et al., 2008) and/or to mediate K+ efﬂux and reactive oxy-
gen species (ROS) driven activation. Recently, we and others have
described mechanistic links between ATP- and particle-mediated
inﬂammasome activation pathways (Riteau et al., 2012). Here we
review the role of active ATP release and purinergic signaling in
NLRP3 inﬂammasome activation.
ATP AND PURINERGIC SIGNALING
Adenosine triphosphate signaling is emerging as an important
mechanism to control various cell functions (Burnstock, 2006;
Praetorius and Leipziger, 2009). Cellular stimulation triggers ATP
release and subsequently activation of purinergic receptors at
the cell surface (autocrine activation) and/or on adjacent cells
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(paracrine activation), thereby regulating or modulating cellular
functions in immunity. Although essentially all cells are able
to release nucleotides, the mechanisms underlying nucleotides
release by epithelial, endothelial, or other non-excitable cells
are poorly understood (Lazarowski et al., 2003; Praetorius and
Leipziger, 2009). After release, eATP interacts with speciﬁc
purinergic receptors or is degraded via different ecto-ATPases to
ADP and AMP and then to adenosine. ATP or its metabolites are
able to signal through different purinergic receptors (P2X, P2Y, or
adenosine P1 receptors; Yegutkin, 2008). In pathological condi-
tions, high levels of ATP are passively released from necrotic cells
and act as a pro-inﬂammatory danger signal, activating theNLRP3
inﬂammasome through binding to the ionotropic P2X7 receptor
(P2X7R; Iyer et al., 2009).
NLRP3 INFLAMMASOME ACTIVATION: ONE OR TWO STEP
SIGNAL?
During NLRP3 inﬂammasome activation, a two-signal model
has been proposed to explain the regulation of IL-1β produc-
tion by macrophages, dendritic cells, or microglial cells. After
a ﬁrst signal induced by LPS triggers accumulation of pro-IL-
1β, exposure to high concentrations of eATP (5 mM) acts as
a powerful second signal to elicit the processing of pro-IL-1β
into mature IL-1β in murine (Perregaux and Gabel, 1994) and
human macrophages (Ataman-Onal et al., 2006) via P2X7R sig-
naling (DiVirgilio, 2007). In contrast, primary human monocytes
were shown to require only one signal because LPS alone was
sufﬁcient to induce secretion of mature IL-1β, with exogenous
ATP acting to further accelerate the LPS-triggered IL-1β pro-
cessing and secretion (Ferrari et al., 2006; Netea et al., 2009). In
addition, primary stimulation of human monocytes with sev-
eral other PAMPs and one DAMP was sufﬁcient to provide
both the ﬁrst and the second signals via a mechanism involving
active release of endogenous ATP to the extracellular environ-
ment with consequent activation of the P2X7R in an autocrine
loop; this allows the triggering of mature IL-1β secretion in a
one step model of inﬂammasome activation (Piccini et al., 2008).
In these studies, eATP and mature IL-1β were measured in the
absence/presence of either, P2X7R pharmacologic inhibitors, or
apyrase, an ATP/ADP degrading enzyme, to demonstrate the roles
of ATP release and purinergic signaling in secretion of mature IL-
1β. Moreover, an inhibitor of ATP degradation ARL67156 greatly
increased both eATP and IL-1β contents, further supporting the
role of endogenously released ATP in secretion of mature IL-1β.
These studies demonstrated that LPS or MSU can trigger ATP
release from stimulated cells, pointing to fundamental roles for
ATP and/or its metabolites as important molecules that medi-
ate the NLRP3 inﬂammasome activation responses to PAMPs or
DAMPS.
Surprisingly, two other recent studies have implicated puriner-
gic signaling but not ATP release in NLRP3 inﬂammasome
activation by suggesting that certain non-nucleotide inﬂamma-
some activators may interact directly with purinergic recep-
tors. First, it was shown that soluble biglycan, an ubiquitous
leucine-rich repeat proteoglycan of the extracellular matrix,
acts as an endogenous danger signal that activates the NLRP3
inﬂammasome and the release of IL-1β without additional
co-stimulatory factors (e.g., exogenous ATP) in murine pri-
mary peritoneal macrophages (Babelova et al., 2009). By signaling
through TLR2/4, biglycan stimulated the expression of NLRP3
and pro-IL-1β mRNA. Biglycan-induced inﬂammasome activa-
tion was completely inhibited by oxidized-ATP (oATP), which
broadly inhibits several P2X and P2Y receptors, and partially
inhibited by KN-62, a selective inhibitor of P2X7R, demonstrat-
ing the involvement of the P2 purinergic receptors. Moreover,
co-stimulation of the biglycan-treated cells with ATP further
increased IL-1β secretion. Nevertheless, the authors claimed direct
activation of the NLRP3 inﬂammasome by biglycan and excluded
an autocrine role for ATP because biglycan did not affect the
secretion of ATP. They proposed that the interaction of biglycan
with both TLR2/4 and purinergic P2X4/P2X7Rs induces receptor
cooperativity and NLRP3 inﬂammasome activation (Babelova
et al., 2009).
Another study characterized inﬂammasome responses to serum
amyloid A (SAA), an acute-phase protein which undergoes up to
a 1000-fold increase in serum levels during inﬂammation, and
which has a pathogenic role in amyloid A-type amyloidosis. SAA
provides a signal for both the induction of pro-IL-1β expression
and NLRP3 inﬂammasome activation, resulting in secretion of
IL-1β without ﬁbril formation and lysosomal destabilization in
human and mouse macrophages (Niemi et al., 2011). Blocking
TLR2 and TLR4 attenuated SAA-induced expression of IL-1β,
whereas inhibition of caspase-1 or P2X7Rby oATPorKN-62 abro-
gated the release of mature IL-1β. However apyrase treatment did
not diminish SAA-mediated IL-1β release and no increase in ATP
levels was observed in response to SAA. Thus, the authors pro-
posed that SAA-induced inﬂammasome activation is mediated by
a direct interaction between SAA and P2X7R and that it is not
associated with the release of ATP or ADP (Niemi et al., 2011). In
conclusion, whether a one- or two-step model of inﬂammasome
activation is involved, ATP and/or purinergic signaling seem to
play key roles in NLRP3 inﬂammasome activation by PAMPs or
DAMPs.
A ROLE FOR ATP IN PARTICLE-INDUCED NLRP3
INFLAMMASOME ACTIVATION
In a recent study, we showed that uric acid, silica, or alum par-
ticles induce the active release of intracellular ATP from human
macrophage to extracellular compartments via mechanisms that
depend on purinergic signaling and connexin/pannexin channels
(Riteau et al., 2012).Weobserved a strong correlationbetweenATP
release and secretion of mature IL-1β after stimulation of phorbol
myristate acetate (PMA)-primed THP1 human macrophages. In
presence of the ﬁrst signal (PMA),MSU, silica, or alum salt crystals
acted as second signal triggers leading to mature IL-1β produc-
tion by these human myeloid cells via ATP release and subsequent
purinergic signaling. Importantly, allopurinol crystals, which
do not elicit NLRP3 inﬂammasome activation (Ataman-Onal
et al., 2006) were also unable to trigger ATP release. In addition,
exposure of LPS-primed murine macrophages to the different
crystalline stimuli also lead to maturation of IL-1β via pathways
dependent on autocrine purinergic signaling loops involving mul-
tiple purinergic receptor subtypes (Riteau et al., 2012). Moreover,
crystal-induced secretion of IL-1β was abrogated by apyrase to
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further conﬁrm the role of ATP and autocrine purinergic signal-
ing in inﬂammasome activation. Nevertheless, P2X7R deﬁciency
in murine macrophages did not change the ability of these cells to
secrete IL-1β even though high and non-speciﬁc concentrations of
the P2X7R inhibitor A740003 severely impaired cytokine produc-
tion. This suggested the involvement of P2 receptor subtypes in
addition toP2X7R. Indeed, several other studies have reported that
blocking or deleting P2X7R did not affect MSU- (Ataman-Onal
et al., 2006), silica- (Iyer et al., 2009), or alum- (Eisenbarth et al.,
2008) induced IL-1β production, thereby implicating roles for
other purinergic receptors in non-pathologic conditions. Previous
reports have indicated that not only ATP but other nucleotides
such as ADP, UTP, or UDP are released into the extracellular
space of mechanically stressed cells, in particular endothelial and
epithelial cells (Di Virgilio et al., 2001; Lazarowski et al., 2003).
These compounds may act on different purinergic receptors to
generate a ﬁnely tuned response. Our data strongly suggest that
members of the two major purinergic receptor families – P2X and
P2Y – are involved because ADP and UTP act only on P2Y-family
receptors. Thus, our study provides a novel link between the par-
ticle internalization- and membrane permeabilization-models of
NLRP3 inﬂammasome activation. Indeed, prior to this analysis,
particulatemolecules and eATPwere considered as two completely
independent stimuli for NLRP3 inﬂammasome activation. The
model presented in Figure 1 summarizes these results and our
model.
In another recent report, the P2Y6 receptor was identiﬁed
as an essential mediator for MSU-induced inﬂammation in the
human THP1 monocyte/macrophage cell line because the speciﬁc
P2Y6 antagonistMRS2578 completely inhibitedMSU-induced IL-
1β production (Uratsuji et al., 2012). Because P2Y6 receptors are
known to be coupled to the activation of phospholipase C (PLC;
Abbracchio et al., 2006), a PLC inhibitor, U-73122, was also tested
and shown to suppress the MSU-induced IL-1β production by
THP1 cells. These results demonstrate that the P2Y6–PLC sig-
naling pathway mediates MSU-induced inﬂammatory responses
in human monocytes (Uratsuji et al., 2012) and thus point to
the involvement of P2Y receptors in particle-induced NLRP3
inﬂammasome activation.
Interestingly, ATP is a potential mediator of neuroinﬂamma-
tion and an extracellular signaling molecule between neurons and
glial cells (Abbracchio et al., 2006). Multiple P2X and P2Y recep-
tor subtypes are expressed by astrocytes, oligodendrocytes, and
microglia (James and Butt, 2002). Thus, microglial cells are a good
model to investigate physiological functions of purinergic recep-
tors in the immune system. First, eATP was shown to cause a large
release of IL-1β from microglial cell lines and from freshly iso-
lated microglial cells by activating the P2X7R (Di Virgilio et al.,
FIGURE 1 | Schematic diagram illustrating the specific cascade
and signaling pathway in LPS-primed macrophages stimulated
with MSU, silica, or alum salt crystals. LPS priming induces transcription
of pro-IL-1β gene and other genes in the nucleus upon activation of the
transcription factor NFkB and subsequent production of pro-IL-1β protein in
the cytosol (1). Particle internalization (2), fusion to lysosome (3) and further
phagolysosome destabilization may lead to cathepsin leakage (4) which
precedes pannexin/connexin (Panx/Conx) hemichannel and purinergic
signaling-dependent intracellular ATP release (5). Extracellular ATP may act
through P2X7 receptor to amplify ATP release in a P2X7 receptor-dependent
way (6). ATP, UTP, or their derived degradation products such as ADP, UDP,
and adenosine, generated by ecto-endonucleases, may act through an
autocrine loop on other purinergic receptor P2X, P2Y, and/or P1 receptors (7)
leading to NLRP3 receptor activation (8). This allows inﬂammasome complex
formation and maturation of pro-IL-1β to IL-1β production (9) and IL-1β
secretion (10).
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1996). Second, stimulation of microglia cells through TLRs has
been proposed to induce the release of endogenous ATP acting
in an autocrine manner to activate the ion channel P2X7 (Ferrari
et al., 1997). Release of ATP and other nucleotides seems to mod-
ulate microglial responses via P2Y and P2X receptors, with the
P2X7 subtype standing out for its known pro-inﬂammatory activ-
ity and for its up-regulation in both a transgenic mouse model
of Alzheimer’s disease and in the brains from Alzheimer’s dis-
ease patients (Parvathenani et al., 2003; McLarnon et al., 2006).
Moreover, another particulate NLRP3 activator, amyloid-β pro-
tein aggregates was shown to promote IL-1β release through
P2X7R-mediated ATP release and therefore to activate the NLRP3
inﬂammasome in microglia (Sanz et al., 2009).
In summary, four different particulate activators, MSU, sil-
ica, alum crystals, and amyloid-β protein aggregates have been
shown to activate theNLRP3 inﬂammasome throughmechanisms
involving ATP release and autocrine purinergic signaling. Based
on the use of pharmacological inhibitors, a role for P2X7R has
often been reported. However, the uncertain selectivity of P2X7R
antagonists (which can vary with concentration and cell type) may
yield questionable or equivocal conclusions. Our recent study used
pharmacological agonists, antagonists, and P2R subtype-deﬁcient
mice to suggest that multiple purinergic signaling pathways are
involved in NLRP3 inﬂammasome regulation through activation
by ATP, ADP, UTP, UDP, and/or adenosine.
A ROLE FOR ATP RELEASE IN CELL DEATH-INDUCED
INFLAMMASOME ACTIVATION
Cells which die in response to non-developmentally programmed
cues, such as the necrosis produced by pressure disruption,
hypoxic injury, or complement-mediated damage, are potent
activators of the innate immune system and can promote ster-
ile inﬂammation through sensing by the NLRP3 inﬂammasome
that results in the subsequent release of the pro-inﬂammatory
cytokine IL-1β. This activation may be triggered in part by ATP
produced by mitochondria and released from damaged cells (Iyer
et al., 2009). Cells which die as part of physiological responses,
such as apoptotic or autophagic cells, are removed from tissues
to prevent immune reactions and maintain tissue homeostasis.
Although apoptotic cells have anti-inﬂammatory properties due
to their surface exposure of anti-inﬂammatory molecules (Fadok
et al., 1998; Cvetanovic et al., 2006), cells dying via autophagy
can trigger pro-inﬂammatory responses through the release of
danger signals that drive NLRP3 inﬂammasome activation (Petro-
vski et al., 2007b; Ghiringhelli et al., 2009; Michaud et al., 2011).
Since the ﬁrst description of autophagy in 1966 (De Duve and
Wattiaux, 1966), numerous studies have described autophagy
as a survival mechanism response to poor nutritional condi-
tions (Gozuacik and Kimchi, 2007; Maiuri et al., 2007). However,
it is now clear that autophagy has a dual role (Codogno and
Meijer, 2005): under certain circumstances, autophagy consti-
tutes a stress adaptation that avoids cell death (and suppresses
apoptosis) by degradation of long-lived proteins and damaged
organelles through the autophago-lysosomal pathway, whereas
in other cellular settings, it constitutes an alternative cell-death
pathway (Petrovski et al., 2007a). Cell dying through autophagy
were shown recently to induce a pro-inﬂammatory response in
human macrophages (Petrovski et al., 2007b). Moreover, phago-
cytosis of human cancer cells dying through autophagy was
shown to trigger NLRP3 inﬂammasome activation and matu-
ration of IL-1β in human macrophages via an ATP-dependent
mechanism (Petrovski et al., 2011). Indeed, multiple manipu-
lations including blockade of K+ efﬂux during phagocytosis,
incubation in the presence of apyrase, addition of P2X7R antag-
onist, or silencing NLRP3 protein expression, all acted to inhibit
this IL-1β secretion response (Petrovski et al., 2011). Moreover,
phagocytosis of murine cells, dying via autophagy by mouse
macrophages was found to activate the NLRP3 inﬂammasome
in the engulﬁng macrophages (Ayna et al., 2012). Studying the
mechanism of inﬂammation illuminated roles for ATP release via
pannexin-1 channels in the autophagic dying cells, phagocyto-
sis of autophagic dying cells, P2X7R activation and subsequent
K+ efﬂux in macrophages as obligatory steps for NLRP3 inﬂam-
masome activation in this model (Ayna et al., 2012). Together,
these studies have demonstrated that ATP release is required for
NLRP3 inﬂammasome activation in both human and murine
macrophages. Some mechanistic details may differ in these mod-
els; during phagocytosis of human autophagic dying cells, ATP
is released by macrophages and acts on macrophage purinergic
receptors in an autocrine loop (Petrovski et al., 2007b), whereas
during engulfment of murine autophagic dying cells, ATP is
released by autophagic dying cells and acts on macrophages in
an paracrine loop (Ayna et al., 2012). Importantly, autophagic
death was reported to contribute to making apoptotic cancer
cells immunogenic (Michaud et al., 2011; Petrovski et al., 2011)
and thereby capable of activating the inﬂammasome in dendritic
cells (Ghiringhelli et al., 2009). These authors ﬁrst showed in a
murinemodel that treatment of cancer cells with anticancer chem-
icals (such as oxaliplatin and mitoxantrone) causes immunogenic
cancer cell death (Ghiringhelli et al., 2009). ATP released from
dying tumor cells was shown to activate P2X7R signaling in den-
dritic cells, leading to inﬂammasome activation and further IL-1β
secretion (Ghiringhelli et al., 2009). These authors also demon-
strated that oxaliplatin- or mitoxantrone-treated tumor cells die
via autophagy which induces an immunogenic response in vivo by
recruiting dendritic cells and T cells into the tumor through the
release of ATP into the extracellular ﬂuid (Michaud et al., 2011).
They subsequently reported that autophagy is essential for the
immunogenic release of ATP from dying cells (Michaud et al.,
2011). Furthermore, such an immunogenic anti-tumor response
could also be elicited when autophagy and cell death was induced
by cytokine depletion. The mechanisms for the NLRP3 acti-
vation triggered through murine cells dying via autophagy are
summarized in Figure 2.
In conclusion, an increasing body of evidence suggests that
ATP and/or purinergic signaling are cornerstone regulators of
NLRP3 inﬂammasome activation in many, but not all, biological
contexts wherein the purinergic pathways do not exclude the exis-
tence of other mechanisms. First, a high amount of passive ATP
release from necrotic cells activates the inﬂammasome through
the P2X7R. Second, PAMP recognition and signaling through
their receptors trigger active ATP release in some cell types such as
human monocytes. Third, phagocytosis of several inﬂammasome
activators following by ATP release appears to be common
Frontiers in Immunology | Inﬂammation January 2013 | Volume 3 | Article 414 | 4
“ﬁmmu-03-00414” — 2013/1/7 — 18:30 — page 5 — #5
Gombault et al. Purinergic signaling and inﬂammasome
FIGURE 2 | Schematic diagram illustrating the mechanisms of NLRP3
inflammasome activation by autophagic dying cells throughATP leakage
and purinergic signaling in murine macrophages or dendritic cells.
Autophagic dying cells release ATP through pannexin-1 (Panx-1) hemichannel
resulting in activation of the purinergic receptor P2X7R on macrophages or
dendritic cells. Phagocytosis of autophagic dying cells and K+efﬂux are
required for NLRP3 inﬂammasome activation in macrophages or dendritic
cells. Since extracellular ATP is rapidly degraded in ADP, AMP, and adenosine,
ATP metabolites could also act through other purinergic receptors and in
particular, ATP and ADP could signal through P2YR. Purinergic signaling and
K+efﬂux result in inﬂammasome assembly and caspase-1 activation leading
to maturation of pro-IL-1β in IL-1β and IL-1β secretion.
pathway for activating the NLRP3 inﬂammasome. Fourth, ATP
leakage from autophagic dying cells and the engulfment of these
cells by macrophages trigger immunity through NLRP3 inﬂam-
masome activation. It will be important to identify the events
linking, on the one hand, phagocytosis of particles or autophagic
dying cells to ATP release by macrophages, and on the other hand,
ATP leakage and engulfment of autophagic dying cells to NLRP3
activation. Finally, the events triggering NLRP3 inﬂammasome
assembly and activation downstream of purinergic signaling are
unknown. Another important issue is that ATP and P2X7R are
not the only purinergic “players” in this response because different
nucleotide metabolites such as ADP, UTP, UDP, and adenosine,
and other members of the purinergic receptor family, i.e., the
P2X, P2Y, and P1 receptors may contribute through complex
purinergic signaling networks. Better understanding of these
mechanisms will facilitate identiﬁcation of new targets for inﬂam-
matory diseases and improve our understanding of the immune
response to cancer.
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